BI Asset Management Fondsmaeglerselskab A S Has $3.93 Million Position in United Therapeutics Corporation $UTHR

BI Asset Management Fondsmaeglerselskab A S cut its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 44.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,629 shares of the biotechnology company’s stock after selling 5,246 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in United Therapeutics were worth $3,931,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Clearstead Advisors LLC lifted its stake in United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 23 shares during the last quarter. Independent Advisor Alliance grew its stake in shares of United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after buying an additional 27 shares during the last quarter. Florida Financial Advisors LLC grew its stake in shares of United Therapeutics by 5.4% during the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after buying an additional 28 shares during the last quarter. NDVR Inc. increased its holdings in shares of United Therapeutics by 5.1% during the fourth quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock worth $300,000 after buying an additional 30 shares in the last quarter. Finally, Principal Securities Inc. increased its holdings in shares of United Therapeutics by 4.7% during the fourth quarter. Principal Securities Inc. now owns 686 shares of the biotechnology company’s stock worth $334,000 after buying an additional 31 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $540.15, for a total value of $5,401,500.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,195,871.40. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $541.55, for a total value of $4,494,865.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $24,462,896.60. This represents a 15.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 634,968 shares of company stock valued at $359,124,602 over the last 90 days. 8.60% of the stock is owned by insiders.

United Therapeutics Price Performance

UTHR opened at $538.30 on Tuesday. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The company’s 50 day moving average price is $563.74 and its two-hundred day moving average price is $524.17. The firm has a market capitalization of $22.85 billion, a price-to-earnings ratio of 19.87, a PEG ratio of 1.75 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the business posted $6.63 EPS. As a group, equities research analysts predict that United Therapeutics Corporation will post 26.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. HC Wainwright increased their price target on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Raymond James Financial initiated coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.